NEW YORK (GenomeWeb) – BG Medicine, which said last month it had laid off more than half of its staff, said in a regulatory document on Friday that it has suspended further payments to its non-employee board directors, effective Oct. 1.

The company said in a document filed with the US Securities and Exchange Commission that it has stopped cash payments and equity compensation to its non-employee directors in order to use its resources for "other operational purposes." It added that it will re-evaluate its policy for paying non-employee directors in 2015.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Jul
12
Sponsored by
Canon BioMedical

This webinar will discuss a project that is analyzing the “Human Brainome” – genome, transcriptome, proteome, and phenome interaction data -- to gain insights into Alzheimer’s disease pathogenesis.